Poster presentation
Open Access
Volume 9 Supplement 1
Proceedings of the Ninth International Society of Sports Nutrition (ISSN) Conference and Expo
Postprandial leucine and insulin responses and toxicological effects of a novel whey protein hydrolysate-based supplement in rats
Journal of the International Society of Sports Nutrition20129(Suppl 1):P30
https://doi.org/10.1186/1550-2783-9-S1-P30
© Toedebusch et al; licensee BioMed Central Ltd. 2012
Published: 19 November 2012
Background
The purpose of this study was: aim 1) compare insulin and leucine serum responses after feeding a novel hydrolyzed whey protein (WPH)-based supplement versus a whey protein isolate (WPI) in rats during the post-absorptive state, and aim 2) to perform toxicological analysis on rats that were fed different doses of the novel WPH-based supplement over a 30-day period.
Methods
In male Wistar rats (~250 g, n = 40), serum insulin and leucine concentrations were quantified up to 120 min after one human equivalent dose of a WPI or the WPH-based supplement. In a second group of rats (~250 g, n = 20), we examined serum/blood and liver/kidney histopathological markers after 30 days of feeding low (1human equivalent dose), medium (3 doses) and high (6 doses) amounts of the WPH-based supplement.
Results
In aim 1, leucine levels were significantly higher at 15 min after WPH vs. WPI ingestion (p = 0.04) followed by higher insulin concentrations at 60 min (p = 0.002). In aim 2, liver and kidney histopathology/toxicology markers were not different 30 days after feeding with low, medium, high dose WPH-based supplementation or water only. There were no between-group differences in body fat or lean mass or circulating clinical chemistry markers following the 30-day feeding intervention in aim 2.
Conclusion
In comparison to WPI, acute ingestion of a novel WPH-based supplement resulted in a higher transient leucine response with a sequential increase in insulin. Furthermore, chronic ingestion of the tested whey protein hydrolysate supplement appears safe.
Declarations
Acknowledgements
This study was funded in full by Scivation, Inc. The authors disclose no financial consulting benefits from Scivation, Inc. or any other companies. Serum leucine analysis was conducted at the Washington University Biomedical Mass Spectrometry Research Resource (supported by NIH Grants RR000954, DK020579 & DK056341). We also graciously acknowledge Charles Wiedmeyer at RADIL for his analyses of serum and blood samples as well as Dr. Chris Lockwood, Dr. Kevin Yarasheski, Joe Company, Jacob Brown, Leigh Gilpin and Dr. Robert Backus for their intellectual insight during the completion of experiments.
Authors’ Affiliations
(1)
Department of Biomedical Sciences, College of Veterinary Medicine; University of Missouri
(2)
Research Animal Diagnostics Laboratory (RADIL)
(3)
NIH/NCRR Mass Spectrometry Resource, Washington University
(4)
School of Medicine, Division of Endocrinology, Metabolism, Lipid Research; Washington University
(5)
Dalton Cardiovascular Research Center, University of Missouri
(6)
Department of Medical Pharmacology and Physiology, School of Medicine; University of Missouri
(7)
Department of Nutrition and Exercise Physiology, College of Environmental Health Sciences; University of Missouri
Copyright
© Toedebusch et al; licensee BioMed Central Ltd. 2012
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
